Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

555
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
555
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

649
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
649
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

3.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
3.3K
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

679
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
679
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

520
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
520
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

1.3K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fundamental advances in the flotation separation of sphalerite and pyrite: Mechanisms, surface chemistry, reagents, and emerging low-alkalinity strategies.

Advances in colloid and interface science·2026
Same author

GCAD: A Computational Framework for Mammalian Genetic Program Computer-Aided Design.

ACS synthetic biology·2026
Same author

Mechanism of Flotation Separation of Rutile and Hornblende Using SHMP and CMC as Depressants.

Langmuir : the ACS journal of surfaces and colloids·2025
Same author

GCAD: a Computational Framework for Mammalian Genetic Program Computer-Aided Design.

bioRxiv : the preprint server for biology·2025
Same author

Advancing models of bubble-particle contact times: A comprehensive review of flotation attachment efficiency prediction.

Advances in colloid and interface science·2025
Same author

Selective Flotation of Rutile from Chlorite Using a Combined CMC and SSF Depressant in a Benzohydroxamic Acid Collector System.

Langmuir : the ACS journal of surfaces and colloids·2025

Related Experiment Video

Updated: Feb 26, 2026

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
09:16

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients

Published on: February 28, 2018

8.1K

Cardiovascular Disease in Acromegaly.

Morali D Sharma1, Anh V Nguyen1, Spandana Brown1

  • 1Houston Methodist Hospital, Houston, Texas.

Methodist Debakey Cardiovascular Journal
|July 26, 2017
PubMed
Summary
This summary is machine-generated.

Acromegaly causes heart problems like cardiomyopathy due to excess growth hormone (GH) and insulin-like growth factor-1 (IGF-1). Treatment can improve heart function and reduce cardiovascular risks.

Keywords:
acromegalyarrhythmiacardiomyopathycoronary artery diseaseheart failurehypertensionvalvular heart disease

More Related Videos

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

22.3K
A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

10.7K

Related Experiment Videos

Last Updated: Feb 26, 2026

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
09:16

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients

Published on: February 28, 2018

8.1K
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

22.3K
A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

10.7K

Area of Science:

  • Cardiology
  • Endocrinology
  • Internal Medicine

Background:

  • Chronic excess of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in acromegaly patients.
  • Development of acromegalic cardiomyopathy with specific cardiac features.

Purpose of the Study:

  • To outline the pathophysiology and features of acromegalic cardiomyopathy.
  • To discuss the impact of treatment on cardiac changes and cardiovascular risks.

Main Methods:

  • Review of existing literature on acromegaly and its cardiac manifestations.
  • Analysis of pathophysiologic changes in acromegalic cardiomyopathy.

Main Results:

  • Acromegalic cardiomyopathy characterized by biventricular hypertrophy and diastolic dysfunction.
  • Progression to systolic dysfunction and congestive heart failure in later stages.

Conclusions:

  • Treatment of acromegaly and cardiovascular risk factors can reverse cardiac changes.
  • Intervention decreases the high risk of cardiovascular complications in acromegaly patients.